Frequency and Intensity of REcurrences in Non-infectious Posterior Uveitis Treated With Fluocinolone Acetonide Implant (FACi): a Multicenter Retrospective Real-world Study

Non-infectious posterior uveitis is a chronic inflammatory eye disease that can lead to irreversible retinal damage and visual impairment due to repeated inflammatory relapses.
The fluocinolone acetonide intravitreal implant is approved for the prevention of inflammatory relapses in this condition, but data from real-world clinical practice remain limited, particularly regarding the intensity of relapses over time.
This multicenter retrospective observational study aims to evaluate the frequency and intensity of inflammatory recurrences in adult patients with non-infectious posterior uveitis treated with a fluocinolone acetonide implant. Clinical and imaging data routinely collected during follow-up will be analyzed over a three-year period to better characterize long-term outcomes, treatment burden, and safety in real-life conditions.

Start Date01 Jun 2026

Sponsor / Collaborator

Nantes University Hospital

NCT06536491

/ Active, not recruitingPhase 1/2

A Randomized, Controlled, Subject- and Evaluator-Masked, Phase 2 Clinical Trial Comparing EC-104 Intravitreal Implant to Ozurdex® for the Treatment of Diabetic Macular Edema (BETTIS-1)

This is a prospective, randomized, subject- and evaluator-masked, Phase 2, multicenter study comparing the safety and efficacy of EC-104-6M high-dose (fluocinolone acetonide [FA] 0.14 mg) implant and EC-104-4M low-dose (FA 0.092 mg) implant to Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg) in subjects with diabetic retinopathy (DR) and center-involving diabetic macular edema (DME), with prior suboptimal clinical response to IVT anti-VEGF therapy who have been previously treated with locally administered corticosteroids without a clinically significant rise in intraocular pressure (IOP).

Start Date19 Aug 2024

Sponsor / Collaborator

Eclipse Life Sciences, Inc.

NCT05592717

/ RecruitingNot ApplicableIIT

An Observational Study of YUTIQ (Fluocinolone Acetonide Intravitreal Implant 0.18 mg) for the Management of Chronic Non-infectious Uveitis

This project is designed to evaluate the efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious uveitis.

Start Date05 Jan 2023

Sponsor / Collaborator

Tianjin Medical University

100 Clinical Results associated with Fluocinolone acetonide micro-insert intravitreous implant

100 Translational Medicine associated with Fluocinolone acetonide micro-insert intravitreous implant

100 Patents (Medical) associated with Fluocinolone acetonide micro-insert intravitreous implant

608

Literatures (Medical) associated with Fluocinolone acetonide micro-insert intravitreous implant

01 Nov 2026·STEROIDS

Menopause-specific associations of organophosphate esters with sex hormones among US women

Article

Author: Fang, Lanlan ; Zheng, Yabing

Organophosphate esters (OPEs) may disrupt hormonal balance, but their specific effects in pre- and post-menopausal women have been underexplored. This investigation delves into the menopause-specific associations of OPEs with sex hormones in the National Health and Nutrition Examination Survey, 2013-2016. We included 817 premenopausal and 657 postmenopausal women. Survey-weighted multivariable linear regression, restricted cubic splines (RCS), principal component analysis (PCA), and quantile-based g computation (qgcomp) models were conducted to investigate the associations of OPE metabolites and OPEs mixture with sex hormones in pre- and postmenopausal women. In postmenopausal women, bis(2-chloroethyl) phosphate (BCEP) and Bis(1,3-dichloro-2-propyl) phosphate (BDCPP) were negatively associated with testosterone (T) (BCEP: β = -0.06 [-0.10, -0.01]; BDCPP: β = -0.07 [-0.13, -0.01]) and free androgen index (FAI) (BCEP: β = -0.08 [-0.13, -0.02]; BDCPP: β = -0.06 [-0.12, -0.01]). Diphenyl phosphate (DPHP) was also negatively associated with FAI (β = -0.08 [-0.14, -0.02]). RCS analyses revealed non-linear exposure-response relationships between DPHP and T, between BDCPP and estrogen (E2), and between BDCPP and DPHP and the T/E2 ratio. PCA and qgcomp analyses consistently found negative associations between the OPEs mixture and T and FAI. Conversely, in premenopausal women, BCEP was linearly and positively associated with sex hormone-binding globulin (SHBG) (β = 0.05 [0.01,0.09]), whereas DPHP showed a nonlinear relationship with SHBG, with a curve rising then plateauing. Overall, OPEs, alone or as mixtures, might lower T and FAI levels in postmenopausal women. In contrast, BCEP and DPHP might increase SHBG levels in premenopausal women.

01 Nov 2026·AMERICAN JOURNAL OF OPHTHALMOLOGY

Comparative Endophthalmitis Rates of Anti-VEGF, Corticosteroid Implants and Anti-Complement Injections: An IRIS Registry Analysis

Article

Author: Meshkin, Ryan S ; Elze, Tobias ; Patel, Nimesh A ; Chaaya, Celine ; Lorch, Alice C ; Miller, John B ; Miller, Joan W ; Goldberg, Eric A ; Zhang, Yi Stephanie ; Ross, Connor J ; Pandiri, Srujay ; Hoyek, Sandra ; Singh, Rishi

PURPOSE:

To evaluate the incidence of endophthalmitis after intravitreal injections using a large, national ophthalmic registry.

DESIGN:

Retrospective clinical cohort study.

METHODS:

Patients in the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) who received intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents, fluocinolone acetonide (Iluvien, Yutiq), avacincaptad pegol (Izervay), pegcetacoplan (Syfovre), or dexamethasone (Ozurdex) were included in this analysis. Data from pediatric and adult patients in the IRIS Registry who were diagnosed with acute endophthalmitis within 30 days after intravitreal injections from 2016 to 2024 were collected.

RESULTS:

The overall incidence of endophthalmitis in adults was 3.5 per 10,000 cases with rates of 3.3 per 10,000 after anti-VEGF, 4.9 per 10,000 after avacincaptad pegol, 6.6 per 10,000 after pegcetacoplan, 10 per 10,000 and 8 per 10,000 after fluocinolone acetonide (Iluvien and Yutiq, respectively), and 12 per 10,000 after dexamethasone implant. The rate of endophthalmitis was significantly higher for corticosteroid implants and pegcetacoplan compared to anti-VEGF injections. Over the past years, there were statistically significant yet small fluctuations in endophthalmitis incidence for anti-VEGF injections ranging from 2.4 per 10,000 in 2021 to 4 per 10,000 in 2020.

CONCLUSIONS AND RELEVANCE:

The incidence of post-injection endophthalmitis is greater with corticosteroid implants and anticomplement therapies. Heightened aseptic vigilance may be warranted with injections that necessitate larger gauge needles, modulate the immune response and/or are prepared from a vial.

10 Sep 2026·Nature

Thermally evaporated perovskite/silicon tandems via formamidinium eutectic

Article

Author: Luo, Chao ; Zhang, Xueling ; Shi, Yu ; Meng, Xin ; Wang, Keli ; Wang, Tao ; Li, Nengxu ; Lin, Ming ; Zhang, Xinyu ; Lee, Ling Kai ; Yin, Wan-Jian ; Zhao, Qing ; Zhu, Zihao ; Gao, Peng ; Guo, Xiao ; Zhou, Qilin ; Hou, Yi ; Jiang, Yuhui ; Hu, Jingcong ; Dong, Zijing ; Wang, Xi ; Bai, Sai ; Chen, Jinxi ; Pei, Fengtao ; Jia, Zhenrong ; Luo, Ran ; Chen, Yifeng ; Wei, Jing ; Yan, Cheng ; Chen, Yu ; Mo, Yi ; He, Rui ; Gao, Jifan ; Niu, Xiuxiu ; Yao, Yuxin ; Du, Xinyi ; Xie, Zhigang ; Ma, Yabin ; Guan, Zhen ; Kan, Chenxia ; Wang, Yuduan

Solution processing remains the dominant route to high-performance perovskite/silicon tandems, but it remains challenging to simultaneously achieve industrial scalability and long-term reliability^1-3. Thermal evaporation is more industrially viable, yet it has not been successfully demonstrated for large-area perovskite/silicon tandems, largely due to the thermal degradation of formamidinium iodide (FAI) during high-temperature evaporation. Here we synthesize a formamidinium-based eutectic that lowers the effective evaporation temperature of FAI by an average of 36 °C-below its degradation threshold-thereby enabling stable FAI evaporation without thermal degradation. As a result, the evaporated perovskite films have enhanced crystallinity and atomic-scale compositional homogeneity. Sequentially evaporated perovskite/silicon tandems achieve a steady-state efficiency of 31.5% (1 cm²). Benefiting from the uniformity of evaporation, we further demonstrate a thermally evaporated large-area perovskite/silicon tandem on a commercial half-cut G12 wafer, delivering a steady-state efficiency of 30% (200 cm²). Scaling the device area from 1 cm² to 200 cm² incurs only a 3.99% relative efficiency loss, representing, to our knowledge, the lowest reported efficiency penalty for area scaling in perovskite-based tandems. The eutectic-based tandem retains 95% of its initial efficiency after 2,000 h of damp-heat ageing (85 °C and 85% relative humidity) and has negligible power loss after 2 months of real-world outdoor operation.

120

News (Medical) associated with Fluocinolone acetonide micro-insert intravitreous implant

16 Oct 2026

·www.biospace.com

Eclipse Life Sciences Announces Positive Topline Results from Phase 2 BETTIS-1 Study Evaluating EC-104 for Diabetic Macular Edema (DME)

RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc. , a privately held clinical-stage biopharmaceutical company developing next-generation therapies for retinal diseases, today announced positive topline results from its BETTIS-1 Phase 2 clinical trial comparing EC-104 fluocinolone acetonide (FA) extended release versus Ozurdex® for the treatment of diabetic macular edema (DME). EC-104 is a novel, completely biodegradable intravitreal corticosteroid implant engineered to deliver approximately six months of durable drug release. The BETTIS‑1 trial met its primary endpoint, demonstrating a favorable safety pro both EC-104 formulations compared to Ozurdex®. Secondary endpoints showed superior clinically meaningful and durable improvement in both best corrected visual acuity and OCT central subfield thickness at 24 weeks, when compared to Ozurdex®. The superiority of EC-104 was demonstrated in a study population of subjects with a previous suboptimal response to anti-VEGF therapy, which represents a significant unmet need and commercial opportunity. “These results position EC-104 as a highly competitive candidate in the DME landscape,” said Scott Cousins, MD, CEO and VP for Research and Development at Eclipse Life Sciences . “The six-month durability, consistent anatomical response, and strong safety pro EC-104’s potential to meaningfully reduce treatment burden. EC-104 continues to show promise as a differentiated corticosteroid option for patients who need longer lasting treatment. We believe these data support advancement into Phase 3 and create a compelling opportunity for strategic collaboration.” Phase 2 BETTIS-1 Topline Findings Primary Endpoint Achieved: EC-104 demonstrated a favorable safety pro low rates of treatment-related adverse events and no unexpected safety signals. Durable Anatomical Response: Both EC-104 formulation groups showed sustained reductions in central subfield thickness (CST) through 24 weeks, consistent with the implant’s six-month release profile. Clinical Benefit in Anti-VEGF-Resistant Subjects: Subjects with documented suboptimal response to prior anti-VEGF therapy exhibited clinically meaningful anatomical improvements, reinforcing EC-104’s potential role as an alternative treatment. Intraocular Pressure (IOP) Profile: Patients with prior corticosteroid tolerance maintained acceptable IOP outcomes in both formulation arms. “These results highlight the potential of EC-104 to reduce treatment burden for patients who struggle with frequent injections and insufficient response to anti-VEGF therapies,” said Victor H. Gonzalez, MD , retina specialist and Founder, Gulf Coast Eye Institute in McAllen, Texas. “An authentic six-month sustained release intravitreal corticosteroid option will be a significant advancement for this population.” Strategic Opportunity With strong Phase 2 data and a well-defined path for late-stage clinical development, regulatory approval and commercialization, Eclipse Life Sciences is exploring partnership opportunities to accelerate Phase 3 initiation and global commercialization. EC-104’s pro it as a differentiated entrant in the multi-billion-dollar DME market where durability and efficacy drive adoption. Next Steps Eclipse Life Sciences plans to engage with regulatory authorities to discuss Phase 3 development of EC-104 and expects to initiate a pivotal program in 2027. Full BETTIS-1 data will be presented at an upcoming ophthalmology conference and will be submitted for publication in a peer-reviewed journal. About Diabetic Macular Edema (DME) DME is the leading cause of vision loss among working-age adults. Although standard of care is initiating treatment with anti-VEGF therapies, many patients experience suboptimal response and require alternative treatments. Intravitreal corticosteroids play a critical role in addressing neuroinflammatory pathways in DME. About Eclipse Life Sciences, Inc. Eclipse Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases. In addition to EC-104, Eclipse is advancing EC-303 for intermediate dry age-related macular degeneration (AMD) and EC-501, a six-month anti-VEGF therapy candidate for wet AMD, DME, and macular edema following retinal vein occlusion (RVO). Investigational product. Not approved by regulatory authorities. For media inquiries: info@eclipselifesciences.com Forward Looking Statements: This press release contains forward looking statements. Actual results may differ materially from those expressed or implied by such statements. Factors that could cause actual results to differ include clinical trial outcomes, regulatory decisions, and market conditions.

Clinical Result

16 Oct 2026

·retinalphysician.com

Eclipse Meets Endpoint in Phase 2 DME Trial

Eclipse Life Sciences announced positive top-line results from its BETTIS-1 phase 2 clinical trial comparing EC-104 fluocinoloneacetonide extended release vs dexamethasone intravitreal implant (Ozurdex; AbbVie) for the treatment of diabetic macular edema (DME). EC-104 is a novel, completely biodegradable intravitreal corticosteroid implant engineered to deliver approximately 6 months of durable drug release, the company said in a press release. According to the company, the BETTIS‑1 trial met its primary endpoint, demonstrating a favorable safety profile across both EC-104 formulations compared to Ozurdex. Secondary endpoints showed superior clinically meaningful and durable improvement in both best-corrected visual acuity and OCT central subfield thickness at 24 weeks, when compared to Ozurdex. The superiority of EC-104 was demonstrated in a study population of subjects with a previous suboptimal response to anti-VEGF therapy, which represents a significant unmet need and commercial opportunity. EC-104 demonstrated a favorable safety profile with low rates of treatment-related adverse events and no unexpected safety signals. Both EC-104 formulation groups showed sustained reductions in central subfield thickness through 24 weeks, consistent with the implant’s 6-month release profile. Subjects with a documented suboptimal response to prior anti-VEGF therapy exhibited clinically meaningful anatomical improvements, reinforcing EC-104’s potential role as an alternative treatment. Patients with prior corticosteroid tolerance maintained acceptable intraocular pressure outcomes in both formulation arms. Eclipse Life Sciences said it plans to engage with regulatory authorities to discuss phase 3 development of EC-104 and expects to initiate a pivotal program in 2027. RP

Clinical ResultPhase 2

12 Oct 2026

·retinalphysician.com

ANI Reports Positive Phase 4 Results for Iluvien in Chronic Uveitis

ANI Pharmaceuticals, Inc. announced that both 6-month and 24-month data from SYNCHRONICITY, its phase 4, open-label, single-arm clinical trial of fluocinolone acetonide intravitreal implant (Iluvien; ANI Pharmaceuticals) in patients with chronic noninfectious uveitis affecting the posterior segment of the eye were presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026 at the American Academy of Ophthalmology 2026 meeting in New Orleans. The data were presented by David R.P. Almeida, MD, MBA, PhD, president and CEO of Erie Retina Research, and principal investigator in SYNCHRONICITY. The trial met both co-primary endpoints with statistical significance in the intent-to-treat (ITT) population (n=108) at 6 months: mean change from baseline in best-corrected visual acuity (BCVA) letter score as measured by ETDRS, and mean change from baseline in central subfield thickness (CST) as measured by SD-OCT. Patients in the ITT population had a mean change from baseline BCVA of +3.6 letters gained (P=.0077) at 6 months (mean BCVA letter score of 62.5 at baseline compared to 65.8 at month 6). Patients in the ITT population also had a mean change from baseline CST of -157.5 µm (P<.0001) at 6 months (mean CST of 505.7 µm at baseline compared to 348.8 µm at month 6). Secondary efficacy outcomes showed that functional and anatomic changes were generally maintained at month 24 in the ITT population. At month 24, mean change from baseline in BCVA letter score in the study eye was +5.5 ETDRS letters in the ITT population. At month 24,mean change from baseline in CST was −171.2 µm in the ITT population. Recurrence was defined as an increase in CST of >100 µm or based on the investigator’s medical judgment. Over the 24-month study period, 86 of 108 study eyes (79.6%) experienced no recurrence of noninfectious inflammation. Among the 22 study eyes (20.4%) that experienced recurrence, median time to recurrence was 168 days. The proportion of study eyes with resolution of macular edema increased during the early treatment period and remained generally stable through month 24 in the ITT population, with 48.2% (n=52/108) of study eyes meeting the criteria for resolution at month 24. Resolution of macular edema was defined as a central subfield thickness (CST) of <325 µm on Heidelberg Spectralis or <315 µm on Zeiss Cirrus. The proportion of study eyes with vascular leakage as measured by widefield fluorescein angiography decreased from 78.7% (n=85/108) at baseline to 55.6% (n=60/108) at month 24 in the ITT population. The most common adverse events seen in SYNCHRONICITY were consistent with prior trials of the fluocinolone acetonide intravitreal implant. In the safety population, 29% of patients (n=31/108) experienced treatment-related treatment-emergent adverse events; the most common were ocular hypertension in 6% of patients (n=7), cataract in 5% of patients (n=5), and visual acuity reduced in 5% of patients (n=5). Separately, 17.6% of patients (19/108) experienced intraocular pressure (IOP) of ≥25 mmHg, 4.6% of patients (5/108) experienced IOP of ≥35 mmHg. IOP-lowering medication was used by 32 patients (29.6%), and 7.4% of patients (8/108) required any laser or surgical IOP-lowering intervention. Cataract surgery was reported in 16 (14.8%) study eyes overall. RP

Clinical ResultPhase 3

100 Deals associated with Fluocinolone acetonide micro-insert intravitreous implant

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C05AA10 S02BA08 S01BA15	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Uveitis	United States	EyePoint, Inc.	12 Oct 2018
Diabetic macular oedema	United States	Alimera Sciences, Inc.	26 Sep 2014
Non-infectious posterior uveitis	United States	Bausch & Lomb, Inc.	08 Apr 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Uveitis, Posterior	Phase 3	United States	ANI Pharmaceuticals, Inc.	05 Oct 2022
Uveitis, Anterior	Phase 3	China	Ocumension Therapeutics	29 Oct 2019
Uveitis, Anterior	Phase 3	China	EyePoint, Inc.	29 Oct 2019
Uveitis, Intermediate	Phase 3	India	EyePoint, Inc.	02 Jun 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EURETINA2025	Not Applicable	Diabetic macular oedema	20	Iluvien (Fluocinolone Acetonide) intravitreal implant (Diabetic Macular Oedema with prior poor/suboptimal response to Ozurdex)	ziwhuylmgt(oibevrrucp) = hmjughzygq hakyreyazh (okmrpyznsb )	Positive	04 Sep 2025
EURETINA2025	Not Applicable	Uveitis	61	Iluvien intravitreal implant	dmwldeaafx(jtvvxwtsql) = Mean BCVA at last follow up improved by 0.2 LogMar in patients who had better than counting fingers (CF) vision pre-Iluvien. In the patients with CF BCVA; 66% improved to 0.1 LogMar. mhjwgrqweh (isvlugskna )	Positive	04 Sep 2025
EURETINA2025	Not Applicable	Diabetic macular oedema	40	ILUVIEN	fgyhevkyzu(ajhfsxhchz) = ifzzjkgubq jobbxpsech (gmxkevbgoy, 15.8) View more	Positive	04 Sep 2025
EURETINA2025	Not Applicable	Diabetic macular oedema	21	ILUVIEN	wdsdyipjok(vpenxtijie) = ukjjcorkdj cueqvouefe (agykbjmonh ) View more	Positive	04 Sep 2025
ARVO2025	Not Applicable	Uveitis \| Ocular Hypotension	24	Boston Type 1 Keratoprosthesis (Kpro) with fluocinolone acetonide intravitreal 0.59 mg implant (Retisert)	ehllsstfvm(pnheoqxutv) = kpfrxhkgio ivlfuzdsan (mbixlbadaf )	Positive	04 May 2025
NCT02746991 (phase III, Pubmed \| Ophthalmol Sci)	Phase 3	Non-infectious posterior uveitis	153	Fluocinolone acetonide implant	njmwhvaxbz(ebnzyrdcfq) = jtyjrlpzqy cyzglitxek (wohplpmzir ) View more	Positive	01 Jan 2024
NCT02746991 (phase III, Pubmed \| Ophthalmol Sci)	Phase 3	Non-infectious posterior uveitis	153	Fluocinolone Acetonide Intravitreal Implant (Sham injection)	njmwhvaxbz(ebnzyrdcfq) = fphtqsizri cyzglitxek (wohplpmzir ) View more	Positive	01 Jan 2024
IRISS, RIVER, PALADIN, REALFAc (EURETINA2023)	Phase 4	Diabetic macular oedema	103	Fluocinolone acetonide intravitreal implant	djfzsodqlc(fpeopiwffp) = gpzfukmonp hirmurxleu (yovzmeuhvq, 20) View more	Positive	05 Oct 2023
CALM (ARVO2023)	Phase 4	Non-infectious posterior uveitis	122	0.18 mg fluocinolone acetonide intravitreal implant	pufdzedfqq(bzcebiyldb) = gwglhphtns tbtijbrare (dvbjjnfdtr ) View more	-	23 Apr 2023
NCT02424019 (PALADIN, EURETINA2022 \| NEWS) Manual	Phase 4	Diabetic macular oedema	159	0.19 mg FAc implant	grllptfpvb(loqplyfmyd) = ufeilncpkh ibiaveyqgo (xzzpffybkk ) View more	Positive	01 Sep 2022
EURETINA 12022 \| EURETINA 22022	Not Applicable	Diabetic macular oedema	-	Iluvien implant	gcgfsqiigt(bcbihqamag) = kwvjtduaaj asymvmzqmr (uhpfthyiiz )	-	01 Sep 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis